3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
37
Carboplatin
28
pembrolizumab
19
Surveys and Questionnaires
11
temsirolimus
10
Radiotherapy
10
Cisplatin
10
Doxorubicin
9
Bevacizumab
9
lenvatinib
8
Docetaxel
8
Nivolumab
7
Metformin
7
Gemcitabine
7
Early Intervention, Educational
7
Counseling
7
Sirolimus
6
Radiation
6
Megestrol Acetate
6
Indocyanine Green
6
olaparib
5
Topotecan
5
Therapeutics
5
Psychiatric Rehabilitation
5
Methods
5
Letrozole
5
Ipilimumab
5
Chemotherapy, Adjuvant
5
ridaforolimus
4
Trastuzumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Endometrial Neoplasms
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled